S&P 500
7,570.40
-0.16%
Dow Jones
52,841.50
+0.23%
Nasdaq 100
29,359.60
-0.67%
Russell 2000
2,967.04
-0.48%
FTSE 100
10,493.60
+0.05%
Nikkei 225
66,612.60
-1.59%

Investing

AstraZeneca Re-Confirms Forecast Following Goof (AZN)

Photo of Paul Ausick
By Paul Ausick Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Drug maker AstraZeneca PLC (NYSE: AZN) has issued a press release re-confirming the company’s December forecast following a load of bad data sent to analysts:

During a routine consensus collection process, confidential Company information was inadvertently embedded in a spreadsheet template sent to the sell-side analyst community that follows the Company. This information is out of date planning information, and does not represent the Company’s view of expected financial performance for the full year 2011 or for future periods.

The company reiterated that it expects earnings for the full 2011 fiscal year to be in the lower half of a range of $7.20-$7.40. AstraZeneca also said that its previously planning assumptions are unchanged.

Contact [email protected] for any questions or corrections.

Disclaimer: Energy Exploration Technologies, Inc. ("EnergyX") has engaged 24/7 Wall St to publish this communication in connection with EnergyX's ongoing Regulation A offering. 24/7 Wall St has been paid in cash and may receive additional compensation. 24/7 Wall St and/or its affiliates do not currently hold securities of EnergyX.

This compensation and any current or future ownership interest could create a conflict of interest. Please consider this disclosure alongside EnergyX's offering materials. EnergyX's Regulation A offering has been qualified by the SEC. Offers and sales may be made only by means of the qualified offering circular. Before investing, carefully review the offering circular, including the risk factors. The offering circular is available at invest.energyx.com/.

Comparisons to other companies are for informational purposes only and should not imply similar results. Past performance is not indicative of future results. Market shortfall are forward‑looking estimates and are subject to substantial uncertainty. Investments in private placements, and start-up investments in particular, are long-term, illiquid, speculative and involve a high degree of risk and those investors who cannot afford to lose their entire investment should not invest in start-ups

Follow 24/7 Wall St. on Google
Photo of Paul Ausick
About the Author Paul Ausick →

Paul Ausick has been writing for 247Wallst.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.

He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.

Continue Reading

Earnings Previews: AstraZeneca, Bakkt, Hyzon
Paul Ausick |

Earnings Previews: AstraZeneca, Bakkt, Hyzon

Here are previews of three earnings reports due for release before markets open on Friday.

Earnings Previews: AstraZeneca, Comcast, Merck
Paul Ausick |

Earnings Previews: AstraZeneca, Comcast, Merck

Two pharmaceutical companies and a top media firm are on tap to report quarterly results before markets open on Thursday.

Paul Ausick |

Verizon Earnings Pummeled by Pension Charges (VZ, T, S, AAPL)

Shares of Verizon Communications Inc. (NYSE: VZ) are down more than -2% in pre-market trading this morning following the company’s…

Paul Ausick |

J.C. Penney Turnaround Still Unlikely

Shares of J.C. Penney traded down about 2% early Tuesday morning, following the inadvertent release of the company's report on…

247alex |

The Least Candid Companies

Brian Katt / Wikimedia Commons / GNU Free Documentation LicenseWhile many investors may think corporate communication is unclear, some companies…

Paul Ausick |

Tiffany Lags, Expects More of the Same

Luxury jewelry retailer Tiffany & Co. (NYSE: TIF) reported first quarter earnings this morning that were a light even though…

Paul Ausick |

Northrop Grumman Tops Estimates, Wary of Defense Cuts

ThinkstockNorthrop Grumman Corp. (NYSE: NOC) reported fourth-quarter and full-year results before markets opened this morning. For the quarter, the defense…

Paul Ausick |

AstraZeneca Drug Fails Trial, Really Hurts Partner (AZN, TRGT)

Pharmaceutical company AstraZeneca plc (NYSE: AZN) is looking for another big winner to replace its Nexium heartburn drug and its…

Paul Ausick |

3M Affirms 2011 Guidance, Expects More in 2012 (MMM)

US conglomerate 3M Co. (NYSE: MMM) today affirmed its full-year 2011 EPS guidance of $5.85-$5.95. Analysts are expecting 2011 EPS…

Top Gaining Stocks

PayPal
PYPL • Vol: 91,051,931
BlackRock
BLK • Vol: 1,583,086
CBRE Group
CBRE • Vol: 1,908,902
CarMax
KMX • Vol: 4,715,131
Invesco
IVZ • Vol: 6,265,161

Top Losing Stocks

Pentair
PNR • Vol: 12,047,011
Erie Indemnity
ERIE • Vol: 641,455
Dell Technologies
DELL • Vol: 13,041,473
Progressive
PGR • Vol: 7,223,690
Western Digital
WDC • Vol: 7,926,134